FDA’s Drug Donation Enforcement Focuses On Sample Integrity
This article was originally published in The Pink Sheet Daily
Guidance on donation of pharmaceuticals to free clinics indicates the agency is unlikely to enforce recordkeeping and inspection requirements of PDMA.
You may also be interested in...
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
FDA may need to undertake an approach similar to the agency's Critical Path initiative in order to facilitate research evaluating its communication efforts